Fairvalue-Calculator Fairvalue-Calculator
EN DE

Genomictree Inc (228760) Fair Value & Analysis

Healthcare · KR · Market cap 313B KRW

Price11,360 KRW
Fair Value8,439 KRW
Upside-25.7%
Quality95/100
Evidence: Low Range 6,329 KRW – 10,548 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Genomictree Inc (228760) currently trades at 11,360 KRW, while our model-based Fair Value estimate is 8,439 KRW — implying the stock looks roughly 25.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR kits, test providers, and nucleic acid transport medium products. The company was founded in 2000 and is headquartered in Daejeon, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Genomictree Inc (228760) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 8,439 KRW versus a price of 11,360 KRW — about −26% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 228760?
Our 21-model fair value for Genomictree Inc is 8,439 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 11,360 KRW.
What is the quality score of 228760?
Genomictree Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.